Form 4: Nautilus Biotechnology Executive Granted Stock Options
SEC Form 4 Filing
Subramanian Sankar, Senior VP at Nautilus Biotechnology, acquires 160,000 stock options at an exercise price of $1.24, vesting over 4 years from January 1, 2025.
Summary
- Subramanian Sankar, Senior VP of Product Development at Nautilus Biotechnology, was granted 160,000 stock options on March 3, 2025.
- The exercise price for these options is $1.24 per share.
- The options vest over a period of 4 years, with 25% vesting on the first anniversary of January 1, 2025, and the remaining 75% vesting monthly thereafter.
- Sankar also has granted power of attorney to Sujal Patel, Matt Murphy, Anna Mowry, Priscilla Chen, Nick Brazell, Zachary Myers and Ben Capps to file SEC documents on his behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard method of compensation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Illumina, Pacific Biosciences, and 10x Genomics also utilize stock options to incentivize their executives.
- The vesting schedule of 4 years with a one-year cliff is a common structure to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| February 21, 2025 | Date of execution of the Power of Attorney. |
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 3, 2025 | Date of the stock option grant and transaction. |
| March 4, 2025 | Date of filing of the Form 4. |
| March 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.